Who is sponsoring NCT04194840?

NCT04194840 is sponsored by Case Comprehensive Cancer Center.

What drugs are being tested in NCT04194840?

Interventions in NCT04194840: physical therapy consult, Cognitive Assessment, Cancer Aging Research Group (CARG) assessment, Medication Review, Nutrition assessment, Laboratory studies, Patient satisfaction questionnaire, Physician Questionnaire, Patient follow-up questionnaire.

What condition does NCT04194840 study?

NCT04194840 studies Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant.

Is NCT04194840 still recruiting?

NCT04194840 is currently completed. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT04194840

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Completed NA Last updated 5 August 2025

What this trial tests

NA trial testing physical therapy consult in Stem Cell Transplant Complications in 20 participants. Completed in 28 March 2025.

Timeline

1 May 2021

Primary endpoint
27 June 2024

28 March 2025

Quick facts

Lead sponsor	Case Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	20
Start date	1 May 2021
Primary completion	27 June 2024
Estimated completion	28 March 2025
Sites	1 location across United States

Drugs / interventions tested

physical therapy consult
Cognitive Assessment
Cancer Aging Research Group (CARG) assessment
Medication Review
Nutrition assessment
Laboratory studies
Patient satisfaction questionnaire
Physician Questionnaire
Patient follow-up questionnaire

Conditions studied

Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
Myeloma — all drugs for Myeloma →
Lymphoma — all drugs for Lymphoma →
Allogeneic and Autologous Stem Cell Transplant — all drugs for Allogeneic and Autologous Stem Cell Transplant →

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Stem Cell Transplant Complications or Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As the average age of individuals undergoing stem cell transplant continues to increase, challenges associated with balancing the side effects of cancer treatments while also managing other medical conditions develop. Studies have shown these individuals develop more treatment related side effects and take longer to leave the hospital due to complications. The purpose of this study is to develop a multiple provider clinic that will help identify any additional needs in the more complicated and generally older transplant patient population. If needed, this clinic will recommend interventions or referrals to the appropriate specialties to the participant and the transplant physician for the participant before your transplant procedure. Examples of potential areas of improvement include a course of physical therapy, nutritional supplements, or modifications of medications, among others with the goal to make your transplant safer and to decrease length of time in the hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stem Cell Transplant Complications

Currently open trials in the same condition.

NCT07509749 — Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) · Phase 2 · recruiting
NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
NCT06541002 — A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors · NA · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04194840 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04194840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing